We hate characterized the determinants of methotrexate (MTX) responsiveness in eight patient-derived cell lines of small-cell lung cancer (SCLC). Clonogenic survival was correlated with factors known to affect sensitivity to drug. NCI-H209 and NCI-H128 were most drug sensitive, with drug concentrations required to inhibit clonogenic survival by 50% with <0.1 M&M MTX. Six cell lines (NCI-H187, NCI-H345, NCI-H60, NCI-H524, NCI-H146, and NCI-N417D) were relatively drug resistant. In all cell lines studied, higher molecular weight MTX-polyglutamates (MTX-PGs) with 3-5 glutamyl moieties (MTX-Glu3 through MTX-Glu5) were selectively retained. Relative resistance to low (1.0 ;M) drug concentrations appeared to be largely due to decreased intracellular metabolism of MTX. Five of the six resistant lines were able to synthesize polyglutamates at higher (10 M&M) drug concentrations, although one resistant cell line (NCI-N417D) did not synthesize higher molecular weight MTX-PGs, even after exposure to 10 MM drug. Two cell lines with resistance to 10 MM MTX (NCI-H146 and NCI-H524) synthesized and retained higher molecular weight MTX-PGs in excess of binding capacity after exposure to 10 MM drug. However, the specific activity of thymidylate synthase in these cell lines was low. MTIX sensitivity in patient-derived cell lines of SCLC requires the ability of cells to accumulate and retain intracellular drug in the form of polyglutamate metabolites in excess of dihydrofolate reductase, as well as a high basal level of consumption of reduced folates in the synthesis of thymidylate.
Introduction
Methotrexate (MTX)' is the most widely used antimetabolite in cancer chemotherapy, demonstrating consistent antitumor activity in osteosarcoma, choriocarcinoma, lymphoma, acute leukemia, breast cancer, cancer ofthe head and neck, and smallcell carcinoma of the lung (SCLC) (1) . Its primary mechanism of action-the inhibition ofdihydrofolate reductase (DHFR)- 1. Abbreviations used in this paper: DHFR, dihydrofolate reductase; dUMP, diocyuridylate; FCS, fetal calf serum; FH2, dihydrofolate; IC3, drug concentration required to inhibit clonogenic survival by 50%; MTX, methotrexate (4-amino-10-methyl-pteroylglutamic acid); MTX-PGs, MTX polyglutamates; MTX-Glutamyll 3, MTX-Glul, MTX-Glu2, MTX-Glu3, MTX-Glu4, and MTX-Glu5, respectively; SCLC, small-cell lung cancer; TS, thymidylate synthase.
is well established, and a variety of possible mechanisms of resistance have been demonstrated in tissue culture experiments and in patient studies.
After entering cells by energy-dependent, carrier-mediated transport (2) , MTX binds stoichiometrically to its target enzyme, DHFR, and prevents repletion of biologically active reduced folate pools necessary for de novo purine and thymidylate synthesis. Since intracellular folates are oxidized only during thymidylate synthesis, the activity of this pathway is a critical determinant of MTX responsiveness (3) (4) (5) (6) . In addition, free drug in excess of intracellular binding capacity is necessary for cytotoxicity. In the absence of free drug, intracellular physiologic folates can compete for binding sites on DHFR, reversing enzyme inhibition (7) (8) (9) . The transformation of MTX to polyglutamyl derivatives results in the formation of active metabolites of the drug that, when present in excess of the intracellular binding capacity, results in prolonged inhibition of DHFR (10) (11) (12) (13) (14) (15) (16) (17) . In addition, MTX polyglutamates (MTX-PGs) may have additional sites of action as inhibitors of aminoimidazole carboxamide ribonucleotide transformylase (de novo purine synthesis) (18) and thymidylate synthase (TS) (19) .
In vitro selection ofMTX-resistant tumor cells has provided detailed insights into diverse mechanisms of drug resistance. Mutants with defective drug transport (20-22) and decreased DHFR affinity for MTX (23-25) have been described. Cellular resistance may also be conferred by amplification of the gene coding for DHFR, resulting in high intracellular target enzyme levels (26) (27) (28) (29) (30) . Low levels of TS, resulting in decreased intracellular folate oxidation (3) (4) (5) (6) , are also associated with resistance.
More recently it has been demonstrated that cells selected for in vitro MTX resistance may be defective in metabolism ofdrug to polyglutamate species (31) .
Despite considerable understanding of in vitro mechanisms of MTX resistance, relatively little is known about the determinants of clinical drug response. Bertino and co-workers (32) were the first to demonstrate that acute rises in intracellular MTX binding capacity could be a determinant ofdrug resistance in patients with acute leukemia. More recently it has been shown that in vivo resistance after MTX treatment may be due to DHFR gene amplification and elevated target enzyme levels (33-37). Still, a complete understanding offactors mediating clinical drug resistance has not been achieved.
In the present studies, we have analyzed potential determinants ofMTX responsiveness in eight cell lines ofSCLC derived from patients who were either newly diagnosed or in relapse after combination chemotherapy including MTX (38) . Cell lines were characterized with respect to growth rate, clonogenic survival after MTX exposure, adequacy of transport to produce saturation of intracellular binding sites, DHFR specific activity, affinity of target enzyme for drug, TS specific activity, and synthesis and retention of MTX-PGs. Cytotoxicity studies. The effects of drug exposure were determined using a soft-agar clonogenic assay (41). Cells (5 X 10' cells/ml) were exposed to drug in complete medium for 24 h, washed three times in iced phosphate-buffered saline, and then plated in 0.37% agarose in complete medium above an agarose feeder layer (42). Cultures were incubated at 37°C under 5% CO2 and colonies counted at 10-20 d with invertedphase microscopy.
DHFR specific activity and affinity for MTX. DHFR activity was determined spectrophotometrically (43) After 1-and 24-h incubation, 2.5 X 106 cells were harvested to determine total intracellular drug and metabolite levels. Bound and free drug levels were determined as described previously (14) . At the end of 24-h drug incubation, the remaining cells were washed in iced PBS three times, resuspended in an equal volume of drug-free complete media, and incubated at 370C for an additional 24 h in order to determine drug efflux patterns. At each time point, cells were processed for intracellular polyglutamate formation as previously described (14) .
Results
Drug sensitivity studies. The clonogenic survival ofthe eight cell lines after a 24-h incubation with 0.1, 1.0, or 10.0 uM MTX fell into two distinct patterns (Fig. 1 ). Both NCI-H209 and NCI-H 128 were highly drug sensitive, with cloning inhibited by >80%bo at 0.1 AM drug. Cell lines NCI-H187, NCI-H345, NCI-H60, NCI-H524, NCI-H 146, and NCI-N417D were considerably more drug resistant, with drug concentrations required to inhibit clonogenic survival by 50% (IC5os) ranging from 0.35 to 5.2 AM drug. There was no consistent relationship between sensitivity and a history ofprior MTX treatment or growth rate. In addition, there was no direct relationship between DHFR specific activity and drug responsiveness. The affinity of DHFR for drug from individual cell lines varied from a Kd of 0.89-2.72 X 10-" M, but again there was no correlation ofthese values with resistance (Table I) . Drug uptake and retention. The intracellular drug profile of all lines was examined after 1 h of drug exposure, at the completion of 24 h incubation, and after 24 h efflux in drug-free media. Parameters studied at each time point included determination of free intracellular drug levels and drug bound to target enzyme, as well as metabolism to and subsequent retention of MTX-PGs.
As shown in Table II The critical determinant of drug retention and prolonged target enzyme saturation was intracellular metabolism of MTX to MTX-PGs with three or more glutamyl groups. These data are shown in Fig. 2 , where incubation times of 1 and 24 h, and 24 h of efflux in drug-free media are shown. No cell line was capable ofsynthesizing higher molecular weight MTX-PGs during the first hour of drug incubation. However, after 24 h incubation, MTX-PGs with three or more glutamyl moieties became the predominant intracellular form ofdrug in both sensitive cell lines, NCI-H209 and NCI-H 128, being present at more than twice the intracellular binding capacity. During the 24-h period in drug-free media, MTX and MTX-Glu2 readily effluxed cells, while the MTX-PGs with longer polyglutamate tails (3-5) were relatively conserved and remained present in excess of intracellular binding capacity at the end of efflux in these two sensitive cell lines, continuing to saturate intracellular binding sites in the absence of extracellular drug.
These results differed from the findings in the six SCLC cell lines resistant to 1-AM drug exposure. In these cell lines, the concentration of higher polyglutamates was much less than the DHFR binding capacity. As shown in Fig. 2 , only small amounts of MTX-Glu3-MTX-Glu5 were formed after 24-h drug incubation of NCI-H1187, NCI-H345, NCI-H60, NCI-H524, NCI-H 146, and NCI-N417D, and at no time were the levels of these higher molecular weight metabolites sufficient by themselves to saturate >69% of the intracellular binding capacity. Notably, free drug levels after 24 h of incubation with 1 AM MTX consisted predominantly of MTX and MTX-Glu2, and were similar to those found in the drug-sensitive NCI-H209 and NCI-H 128 cell lines. However, after the 24-h incubation in drug-free media, MTX and MTX-Glu2 effluxed readily, and although the small quantities of longer polyglutamates were retained during efflux, their initial synthesis was insufficient to maintain drug in excess of the binding capacity. Closer study of individual polyglutamate metabolites confirmed that, as determined in prior experiments with breast cancer cell lines (13) and small-cell cell lines (17), drug retention correlates with glutamyl chain length. Thus, for all cell lines after a 24-h exposure to 1.0 1sM MTX, only 4-24% of parent drug present at the end of drug incubation remained after 24-h efflux, while 25% of MTX-Glu2, 70% of MTX-Glu3, 75% of MTX-Glu4, and 83% of MTX-Glu5 were retained. Of the cell lines with relative resistance to 1 MuM MTX, only NCI-H 187 synthesized small amounts of MTX-Glu5 (<1% of total intracellular drug). No other resistant line synthesized polyglutamates larger than MTX-Glu4, and this metabolite wvas consistently <4% of total intracellular drug after 1 MM incubation for 24 h. However, after the same drug exposure in the MTX-sensitive cell lines, MTX-Glu4 and MTX-Glu3 accounted for at least 20% of total intracellular drug.
Intracellular formation and retention ofMTX-PGs after 10 MMMTXexposure: determinants ofsensitivity. The determinants of tumor cell sensitivity, including drug accumulation, metabolism, and retention, were examined at 10 MuM MTX in the six resistant cell lines that had low levels of MTX polyglutamation after 1-MuM drug incubation. As shown in Fig. 3 and Table II, at the higher drug concentration, total intracellular drug levels after both 1-and 24-h incubation were 3.4-to 10-fold higher than the corresponding level achieved at 1.0 MM MTX. The intracellular binding capacity as measured by DEAE-Sephacel chromatography at 1 h was somewhat higher (1.5-4.9 times) in cells exposed to 10 MuM drug as compared with the binding capacity at 1 MM. These differences became less marked with continued drug exposure, and measured binding capacities were similar at 24 h incubation and effiux for cells exposed to either 1 or 10 MM drug. The most remarkable changes in intracellular drug levels in cells exposed to 10 MM MTX was a general increase in free drug levels at all measured time points, including after 24 h of effiux in drug-free media (Table II) . Thus, while free drug after effux had been between 0.13 and 0.67 nM/g after 1.0-MM exposure, free drug levels after 10.0 MM incubation and 24-h effiux increased more than fourfold in all cell lines tested except NCI-N417D, which remained at 0.13 nM/g. Again, the critical MM MTX for I h, 24 h, and subsequent 24-h efflux in drug-free media.
determinant for drug retention above intracellular binding capacity and drug sensitivity was the extent of metabolism to MTX-Glu3-.5
As shown in Fig. 3 , the absolute amounts ofhigher molecular weight MTX-PGs increased substantially after 10 MtM drug exposure. NCI-H345, NCI-H60, and NCI-H146, which had previously synthesized no MTX-Glu5, now synthesized levels of this metabolite equal to or greater than those found in the sensitive cell lines after 1.0 MM drug exposure. Further, intracellular levels of MTX-Glu3 and MTX-Glu4 were increased after 10uM MTX exposure in all cell lines as compared with their levels after 1 MM drug.
As had been observed after exposure to 1.0 MM drug, MTX and MTX-Glu2 rapidly effluxed from the cells in drug-free media, while higher molecular weight metabolites were again selectively retained (Fig. 3) . Sufficient quantities of these derivatives were present after the 24-h incubation to more than saturate DHFR after 24 h in drug-free media in all cell lines except NCI-N417D (Fig. 3 ) These increases were associated with >90% inhibition of colony formation in three of the six cell lines (Fig. 1) when MTX-PG levels were sustained during the period ofdrug efflux.
NCI-H 146, NCI-H524, and NCI-N417D remained relatively drug resistant (Fig. 1) 
Discussion
In these experiments we have studied parameters capable of modulating MTX responsiveness in eight patient-derived lines ofSCLC. The degree ofdrug resistance observed in these clinical specimens is relatively low compared to that obtainable in vitro with serial selective passage in increasing drug concentrations. Even in the most resistant of these clinically derived cell lines, clonogenic survival was <50% control after a 24-h exposure to 10 AM drug. However, these cell lines did differ over a 100-fold range in their sensitivity to MTX, and their isolation provides a unique opportunity to examine the factors responsible for clinical drug resistance. Previous examination of the determinants of MTX toxicity in cultured cells and in experimental in vivo models has provided evidence that the ability to kill cells is a function of the presence of free intracellular antifolate. Under conditions that simulated clinical exposure oftumor cells to MTX (1 MM drug for 24 h), drug saturated the intracellular binding capacity in all cell lines. Drug transport did not, therefore, appear to be a limiting factor responsible for resistance in these cells. The critical determinant of sensitivity to 1.0 p'M MTX was the ability of cells to form MTX-PGs with 3-5 glutamyl moieties. There was a direct relationship between the formation ofthe higher polyglutamates and intracellular retention ofdrug after removal of extracellular MTX. Two cell lines (NCI-H209 and NCI-H 128) were highly sensitive to 1.0 MM drug exposure (no colony survival), and in both of these lines this exposure produced sufficient MTX polyglutamates to exceed the drug-binding capacity by >50% for 24 h after removal of extracellular drug. In the six remaining lines with relative resistance to 1.0 AM drug, formation of these metabolites (MTX-Glu3 to MTX-Glu5) was insufficient to produce excess free intracellular antifolate for 24 h, although the general pattern of retention of higher polyglutamates was similar to that observed in drug-sensitive lines (Fig. 2) .
Three of the six cell lines with relative resistance to 1.0 AM MTX were unable to survive exposure to 10 MM drug (NCI-H345, NCI-H60, and NCI-H187). In these three cell lines, exposure to the higher drug concentrations resulted in sufficient synthesis of MTX-Glu3 to MTX-Glu5 for prolonged maintenance of free intracellular drug (Fig. 3) .
Three cell lines demonstrated greater resistance to MTX; NCI-H1146, NCI-H524, and NCI-N417D were capable of significant survival (>20% control colony formation) after exposure to 10.0 MM drug. In NCI-N417D, MTX polyglutamation remained inefficient during exposure to high drug concentrations.
After 24-h incubation in 10 MM drug, MTX-Glu5 was undetectable, and other high molecular weight metabolites were found only in small quantities.
In NCI-H 146 and NCI-H524, the specific activity ofTS was low (Table I) . Since de novo thymidylate synthesis is the only pathway by which reduced folates are oxidized to inactive dihydrofolate, the activity of TS is crucial to antifol sensitivity. Similar results have been reported by Washtien (6) , who studied TS levels in five cultured human gastrointestinal tumor cell lines and found a negative correlation between MTX sensitivity and TS specific activity (6). increases in DHFR might overwhelm intracellular free drug and make sufficient enzyme available for reduction of oxidized folates. In both the human KB cells and the patient-derived SCLC cell lines, this induction was dose dependent, but limited, in that intracellular drug binding capacity after 24 h of MTX exposure was generally similar at 1.0-and at 10.0-MM incubations.
Many factors seemed oflesser importance in predicting drug sensitivity (Table I ). There was a poor correlation between doubling time and drug sensitivity. Further, the measured differences in target enzyme affinity for drug were small in comparison to the 250-fold decrease in affinity reported to confer in vitro resistance (23).
We have previously observed elevated DHFR levels associated with gene amplification in an SCLC patient in clinical relapse after treatment with single-agent, high-dose MTX (33). However, this phenomenon was not observed in any ofthe present cell lines, five ofwhich were derived from patients receiving low doses of MTX as a component of combination chemotherapy.
In summary, we have studied the variables that are known to modulate MTX responsiveness in eight clinically derived cell lines ofSCLC. In six ofeight lines, the ability ofcells to synthesize and retain MTX-PGs in excess of DHFR binding capacity was a primary determinant ofsensitivity. MTX metabolism to MTXPGs was dose dependent, and could be increased by raising extracellular drug concentration. Importantly, polyglutamate formation was also time dependent; even the most sensitive SCLC cell lines in this series were unable to metabolize MTX to polyglutamate species after 1-h exposure to drug. Since our data indicate that synthesis and retention of these higher molecular weight species are critical for cytotoxicity, the usual clonogenic assay-which exposes tumor cells to drug for only 1 h-is very limited in determining cellular sensitivity to this drug. Although prolonged saturation of target enzyme was necessary for toxicity, it was not in itself sufficient. Resistance to MTX could be maintained despite the presence of free intracellular drug in two cell lines that had low specific activity of thymidylate synthase. Thus, MTX resistance in human SCLC is multifactorial, and may or may not be overcome at high drug concentrations.
